Drug
Apraglutide clinical trials
Also written FE203799.
- studies test it
- 12
- open now
- 1
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the apraglutide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
12 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
VectivBio AG (9) · GlyPharma Therapeutics (3)
Studies
Open first, then newest update. How each study uses apraglutide is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study to Investigate the Efficacy and Safety of Apraglutide Compared With Placebo in Adult Participants With Short Bowel Syndrome Associated With Intestinal Failure (SBS-IF)RecruitingPhase 3VectivBio AGNCT07742735Written as Apraglutide
- Proof-of-concept Trial of Apraglutide in Acute Graft Versus Host Disease (aGVHD)TerminatedPhase 2VectivBio AGNCT05415410Written as Apraglutide
- A Phase 1 Open-Label Evaluation of the Pharmacokinetics and Safety of a Single Dose of Apraglutide in Subjects With Normal and Impaired Hepatic FunctionCompletedPhase 1VectivBio AGNCT05706623Written as Apraglutide
- Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.Active, not recruitingPhase 3VectivBio AGNCT05018286Written as Apraglutide
- Metabolic Balance Study of Apraglutide in Patients With Short Bowel Syndrome, Intestinal Failure (SBS-IF) and Colon-in-Continuity (CIC)CompletedPhase 2VectivBio AGNCT04964986Written as Apraglutide
- Trial to Evaluate Efficacy and Safety of Apraglutide in SBS-IFCompletedPhase 3VectivBio AGNCT04627025Written as apraglutide
- Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral SupportCompletedPhase 1/2GlyPharma TherapeuticsNCT03415594Written as FE203799 GLP-2 analogue
- Relative Bioavailability of a New Presentation of Apraglutide Versus the Reference FormulationCompletedPhase 1VectivBio AGNCT06002555Written as Apraglutide
- Study of Pharmacokinetics and Safety of Apraglutide in Participants With Normal and Impaired Kidney Function.CompletedPhase 1VectivBio AGNCT04699032Written as Apraglutide
- Evaluation of Apraglutide on Gastric EmptyingCompletedPhase 1VectivBio AGNCT05995704Written as Apraglutide
- Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal InsufficiencyCompletedPhase 1/2GlyPharma TherapeuticsNCT03408132Written as FE203799
- Safety, Tolerability, PK/PD of FE 203799 in Adults With LymphomasWithdrawnPhase 1/2GlyPharma TherapeuticsNCT03417765Written as FE 203799
Codes
What other systems call apraglutide · ClinicalTrials.gg INT001414
- MeSH (NLM) C000710330apraglutideConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) CVQ1IAY2G6APRAGLUTIDEConfirmed FDA, NLM
- NCI Thesaurus C171811ApraglutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000710330 | apraglutide | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | CVQ1IAY2G6 | APRAGLUTIDE | Confirmed FDA, NLM |
| NCI Thesaurus | C171811 | Apraglutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.